| Literature DB >> 28708993 |
Howard Y Chang1, Kari C Nadeau2.
Abstract
Dupilumab is a fully human IgG4 monoclonal antibody directed against the IL-4Rα subunit of IL-4 and IL-13 receptors. It blocks the signaling pathways of IL-4 and IL-13, key cytokines that drive type 2 inflammatory response. In March 2017, dupilumab was approved for use in the treatment of atopic dermatitis (eczema). To view this Bench to Bedside, open or download the PDF.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28708993 DOI： 10.1016/j.cell.2017.06.046
Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 41.582